BioCentury | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
BioCentury | Feb 2, 2017
Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
BioCentury | Sep 19, 2016
Company News

Duchesnay, Alliance Pharma deal

The partners added Germany, France, Italy and six additional undisclosed EU countries to a 2015 deal granting Alliance rights to market Diclectin doxylamine/pyridoxine in the U.K. Alliance said it will pay L1 million ($1.3 million)...
BioCentury | Aug 22, 2016
Clinical News

Lucassin terlipressin: Phase III started

Mallinckrodt began the double-blind, placebo-controlled, North American Phase III CONFIRM trial to evaluate 1 mg IV Lucassin every 6 hours in about 300 patients. Lucassin is approved outside the U.S. and Canada to treat Type...
BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: K-Ras (KRAS); calmodulin; protein kinase C (PKC)

Cancer INDICATION: Pancreatic cancer Mouse studies suggest inhibiting the KRAS- calmodulin interaction by activating PKC could help treat KRAS-driven pancreatic cancer. In a human pancreatic cell line harboring oncogenic KRAS , the PKC activator prostratin inhibited...
BioCentury | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Protein kinase C (PKC) α (PRKCA); PKC δ (PRKCD); PKC θ (PRKCQ)

Cancer INDICATION: Cancer In vitro studies have identified bryostatin-derived PKC modulators that could help treat cancer and other indications. Chemical synthesis and in vitro testing identified three bryostatin analogs that bound the PKC isoforms α,...
BioCentury | Jun 2, 2014
Company News

Alliance Pharma board of directors update

Alliance Pharma plc (LSE:APH), Chippenham, U.K. Business: Neurology, Cardiovascular, Dermatology Appointed: Andrew Smith, a director, as chairman; he succeeds Michael Gatenby WIR Staff Cardiovascular Dermatology Neurology...
BioCentury | Jan 20, 2014
Company News

Alliance Pharma, Bayer sales and marketing update

Alliance Pharma's Alliance Pharmaceuticals Ltd. subsidiary acquired from Bayer rights to Irenat sodium perchlorate monohydrate in Germany to diagnose and treat hyperthyroidism. The product marketed in the country, where it had sales of €800,000 ($1.1...
BioCentury | Nov 25, 2013
Company News

Aphios neurology, ophthalmic news

Aphios said it will spin off a wholly owned subsidiary, Amylon LLC, to develop and commercialize APH-1104 to treat mild to moderate Alzheimer's disease (AD) and other disorders, such as Down's syndrome, Parkinson's disease (PD)...
Items per page:
1 - 10 of 41